Robin Schürfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robin Schürfeld has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Anke Tönjes
Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig
4 shared publicationsEkaterine Baratashvili
Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig
4 shared publicationsMatthias Blüher
Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig
4 shared publicationsAnette Bachmann
Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig
3 shared publicationsBenjamin Sandner
Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig
3 shared publicationsMichael Stumvoll
Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig
3 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1804956
Inverse association of circulating kallikrein-related peptidase 7 with renal function and mortality risk in patients with chronic kidney disease
Introduction: Kallikrein-related peptidase 7 (KLK7) is a protease implicated in metabolic disease and obesity. Patients with chronic kidney disease (CKD) exhibit several cardio-metabolic comorbidities and increased mortality. The goal of this study was to investigate the associations of KLK7 levels with renal function and clinical outcomes in patients with CKD. Methods: Baseline KLK7 serum levels were cross-sectionally related to renal and cardiometabolic markers in the Leipzig-CKD cohort (n=542). Longitudinal Cox Regression analyses (n=472) were performed to associate baseline circulating KLK7 concentrations and risk of major adverse renal (MARE) and cardiovascular (MACE) events, as well as all-cause mortality. Additionally, mRNA expression of Klk7 and related genes was examined in CKD versus control mice using bulk RNA sequencing. Results: KLK7 levels were inversely associated with markers of renal function, i.e. estimated glomerular filtration rate (eGFR), and inflammation, i.e. C-reactive protein, in multivariable regression. Longitudinal analyses associated higher baseline KLK7 with lower all-cause (adjusted HR [95% CI]: 0.65 [0.49–0.86], p=0.003) and non-cardiovascular (adjusted HR [95% CI]: 0.56 [0.40–0.78], p=0.001) mortality over a median follow-up of 7.6 years. A KLK7 threshold of 1383.6 pg/ml stratified patients into low- and high-risk groups for mortality. No associations were found for MARE or MACE. In tissues of CKD and control mice, no significant changes in Klk7 mRNA expression were found. Discussion: Circulating KLK7 associates inversely with renal function and inflammation, likely reflecting reduced renal clearance. Higher circulating KLK7 independently predicts lower all-cause mortality, whereas baseline KLK7 was not related to composite renal and CV outcomes.
- 7 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1804956
Open AccessInverse association of circulating kallikrein-related peptidase 7 with renal function and mortality risk in patients with chronic kidney disease
Introduction: Kallikrein-related peptidase 7 (KLK7) is a protease implicated in metabolic disease and obesity. Patients with chronic kidney disease (CKD) exhibit several cardio-metabolic comorbidities and increased mortality. The goal of this study was to investigate the associations of KLK7 levels with renal function and clinical outcomes in patients with CKD. Methods: Baseline KLK7 serum levels were cross-sectionally related to renal and cardiometabolic markers in the Leipzig-CKD cohort (n=542). Longitudinal Cox Regression analyses (n=472) were performed to associate baseline circulating KLK7 concentrations and risk of major adverse renal (MARE) and cardiovascular (MACE) events, as well as all-cause mortality. Additionally, mRNA expression of Klk7 and related genes was examined in CKD versus control mice using bulk RNA sequencing. Results: KLK7 levels were inversely associated with markers of renal function, i.e. estimated glomerular filtration rate (eGFR), and inflammation, i.e. C-reactive protein, in multivariable regression. Longitudinal analyses associated higher baseline KLK7 with lower all-cause (adjusted HR [95% CI]: 0.65 [0.49–0.86], p=0.003) and non-cardiovascular (adjusted HR [95% CI]: 0.56 [0.40–0.78], p=0.001) mortality over a median follow-up of 7.6 years. A KLK7 threshold of 1383.6 pg/ml stratified patients into low- and high-risk groups for mortality. No associations were found for MARE or MACE. In tissues of CKD and control mice, no significant changes in Klk7 mRNA expression were found. Discussion: Circulating KLK7 associates inversely with renal function and inflammation, likely reflecting reduced renal clearance. Higher circulating KLK7 independently predicts lower all-cause mortality, whereas baseline KLK7 was not related to composite renal and CV outcomes.
- Open Access
- 25 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 167-169
An adipocytokine signature improves diagnostic accuracy for people living with lipoedema
Lipoedema is a chronic adipose tissue disorder often misdiagnosed as obesity due to overlapping symptoms and a lack of biomarkers. In this study, we analysed 13 adipocytokines in 79 women and identified chemerin, FGF21 and adiponectin as key biomarkers for distinguishing lipoedema. Decision tree models achieved up to 95% sensitivity, supporting the potential of these biomarkers for improving diagnostic accuracy, particularly in women with overweight or obesity.
- 25 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 167-169
Open AccessAn adipocytokine signature improves diagnostic accuracy for people living with lipoedema
Lipoedema is a chronic adipose tissue disorder often misdiagnosed as obesity due to overlapping symptoms and a lack of biomarkers. In this study, we analysed 13 adipocytokines in 79 women and identified chemerin, FGF21 and adiponectin as key biomarkers for distinguishing lipoedema. Decision tree models achieved up to 95% sensitivity, supporting the potential of these biomarkers for improving diagnostic accuracy, particularly in women with overweight or obesity.
- 1 December 2025
- Published by Springer Nature in Die Diabetologie
- Vol. 22 (1) , 54-55
Eloralintid als neuer Amylinrezeptoragonist zum Gewichtsmanagement
- 1 December 2025
- Published by Springer Nature in Die Diabetologie
- Vol. 22 (1) , 54-55
Eloralintid als neuer Amylinrezeptoragonist zum Gewichtsmanagement
- 17 October 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Proenkephalin predicts kidney function and major adverse kidney events in CKD
Background and hypothesis: The endogenous opioid proenkephalin (PENK) has been identified as an independent risk marker for acute cardiovascular diseases and acute kidney injury. However, its regulation, its association with other cardiometabolic markers and its prognostic role in patients with chronic kidney disease (CKD) have not been thoroughly investigated. Methods: PENK serum levels were cross-sectionally related to renal and cardiometabolic markers across three large cohorts (total N = 4722), including the Leipzig-CKD cohort (N = 581), as well as the population-based LIFE-Adult (N = 3093) and Sorbs (N = 1048) cohort. Furthermore, a longitudinal analysis was performed in the Leipzig-CKD cohort to assess the association between circulating PENK levels at baseline and a composite 4-point major adverse renal events (4P-MAKE) endpoint comprising incident or worsening kidney disease, development of kidney failure (KF) requiring kidney replacement therapy or kidney transplantation, and renal deaths. Results: In the entire cross-sectional cohort (N = 4722), PENK levels were strongly and inversely correlated with markers of renal function, i.e. estimated glomerular filtration rate (eGFR), creatinine and urinary albumin–creatinine ratio. In multivariable analysis, eGFR was the strongest, independent and inverse predictor of circulating PENK levels after adjustment for age and sex, as well as markers of obesity, glucose intolerance, dyslipidemia and inflammation. Multivariable Cox regression analysis revealed that baseline circulating PENK levels were strongly associated with an increased risk of the 4P-MAKE over a median follow-up of 8.7 years. Each doubling of PENK levels was associated with a >2-fold increase in the risk of developing 4P-MAKE, even after adjusting for various clinical and metabolic variables. PENK provided added value for predicting adverse renal outcomes. Conclusions: PENK levels are strongly, independently, and inversely associated with renal function in cross-sectional analysis. Furthermore, baseline circulating PENK levels are predictive of a 4P-MAKE in patients and added independent, prognostic value for identification of patients at risk for adverse renal outcomes.
- 17 October 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Proenkephalin predicts kidney function and major adverse kidney events in CKD
Background and hypothesis: The endogenous opioid proenkephalin (PENK) has been identified as an independent risk marker for acute cardiovascular diseases and acute kidney injury. However, its regulation, its association with other cardiometabolic markers and its prognostic role in patients with chronic kidney disease (CKD) have not been thoroughly investigated. Methods: PENK serum levels were cross-sectionally related to renal and cardiometabolic markers across three large cohorts (total N = 4722), including the Leipzig-CKD cohort (N = 581), as well as the population-based LIFE-Adult (N = 3093) and Sorbs (N = 1048) cohort. Furthermore, a longitudinal analysis was performed in the Leipzig-CKD cohort to assess the association between circulating PENK levels at baseline and a composite 4-point major adverse renal events (4P-MAKE) endpoint comprising incident or worsening kidney disease, development of kidney failure (KF) requiring kidney replacement therapy or kidney transplantation, and renal deaths. Results: In the entire cross-sectional cohort (N = 4722), PENK levels were strongly and inversely correlated with markers of renal function, i.e. estimated glomerular filtration rate (eGFR), creatinine and urinary albumin–creatinine ratio. In multivariable analysis, eGFR was the strongest, independent and inverse predictor of circulating PENK levels after adjustment for age and sex, as well as markers of obesity, glucose intolerance, dyslipidemia and inflammation. Multivariable Cox regression analysis revealed that baseline circulating PENK levels were strongly associated with an increased risk of the 4P-MAKE over a median follow-up of 8.7 years. Each doubling of PENK levels was associated with a >2-fold increase in the risk of developing 4P-MAKE, even after adjusting for various clinical and metabolic variables. PENK provided added value for predicting adverse renal outcomes. Conclusions: PENK levels are strongly, independently, and inversely associated with renal function in cross-sectional analysis. Furthermore, baseline circulating PENK levels are predictive of a 4P-MAKE in patients and added independent, prognostic value for identification of patients at risk for adverse renal outcomes.
- 19 February 2025
- Published by Springer Nature in Die Diabetologie
- Vol. 21 (2) , 219-220
Adipositastherapie und Diabetesprävention mit Tirzepatid
- 19 February 2025
- Published by Springer Nature in Die Diabetologie
- Vol. 21 (2) , 219-220
Adipositastherapie und Diabetesprävention mit Tirzepatid
- Open Access
- 13 November 2023
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 31 (1)
False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade
Measurements of plasma metanephrines and methoxytyramine provide a sensitive test for diagnosis of pheochromocytoma/paraganglioma. False-positive results remain a problem, particularly in patients taking norepinephrine reuptake-blocking drugs. Therefore, in this retrospective observational study, we measured plasma metanephrines and methoxytyramine in 61 patients taking norepinephrine reuptake blockers (tricyclic antidepressants or serotonin–norepinephrine reuptake inhibitors) and 17 others taking selective serotonin reuptake inhibitors, all without pheochromocytoma/paraganglioma. We highlight a singular case with strongly elevated plasma normetanephrine and methoxytyramine concentrations associated with norepinephrine reuptake blockade. Data were compared to results from 252 and 1804 respective patients with and without tumors. Plasma normetanephrine was 40% higher (P < 0.0001) in patients on norepinephrine reuptake blockers and methoxytyramine was 127% higher (P = 0.0062) in patients taking tricyclic antidepressants compared to patients not taking uptake blockers and without tumors. The corresponding false-positive rates rose (P < 0.0001) from 4.8% to 23.0% for normetanephrine and from 0.9% to 28.6% for methoxytyramine. Selective serotonin reuptake inhibitors did not increase plasma concentrations of metabolites. In the highlighted case, plasma normetanephrine and methoxytyramine were elevated more than six times above upper reference limits. A pheochromocytoma/paraganglioma, however, was excluded by functional imaging. All biochemical test results normalized after discontinuation of norepinephrine reuptake blockers. These findings clarify that norepinephrine reuptake blockers usually result in mild elevations of normetanephrine and methoxytyramine that, nevertheless, significantly increase the number of false-positive results. There can, however, be exceptions where increases in normetanephrine and methoxytyramine reach pathological levels. Such exceptions may reflect failure of centrally mediated sympathoinhibition that normally occurs with the norepinephrine reuptake blockade.
- 13 November 2023
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 31 (1)
Open AccessFalse-positive results for pheochromocytoma associated with norepinephrine reuptake blockade
Measurements of plasma metanephrines and methoxytyramine provide a sensitive test for diagnosis of pheochromocytoma/paraganglioma. False-positive results remain a problem, particularly in patients taking norepinephrine reuptake-blocking drugs. Therefore, in this retrospective observational study, we measured plasma metanephrines and methoxytyramine in 61 patients taking norepinephrine reuptake blockers (tricyclic antidepressants or serotonin–norepinephrine reuptake inhibitors) and 17 others taking selective serotonin reuptake inhibitors, all without pheochromocytoma/paraganglioma. We highlight a singular case with strongly elevated plasma normetanephrine and methoxytyramine concentrations associated with norepinephrine reuptake blockade. Data were compared to results from 252 and 1804 respective patients with and without tumors. Plasma normetanephrine was 40% higher (P < 0.0001) in patients on norepinephrine reuptake blockers and methoxytyramine was 127% higher (P = 0.0062) in patients taking tricyclic antidepressants compared to patients not taking uptake blockers and without tumors. The corresponding false-positive rates rose (P < 0.0001) from 4.8% to 23.0% for normetanephrine and from 0.9% to 28.6% for methoxytyramine. Selective serotonin reuptake inhibitors did not increase plasma concentrations of metabolites. In the highlighted case, plasma normetanephrine and methoxytyramine were elevated more than six times above upper reference limits. A pheochromocytoma/paraganglioma, however, was excluded by functional imaging. All biochemical test results normalized after discontinuation of norepinephrine reuptake blockers. These findings clarify that norepinephrine reuptake blockers usually result in mild elevations of normetanephrine and methoxytyramine that, nevertheless, significantly increase the number of false-positive results. There can, however, be exceptions where increases in normetanephrine and methoxytyramine reach pathological levels. Such exceptions may reflect failure of centrally mediated sympathoinhibition that normally occurs with the norepinephrine reuptake blockade.
- 9 November 2023
- Published by Springer Nature in Die Diabetologie
- Vol. 20 (1) , 147-148
Once-weekly basal ultralong-acting insulin administration in type 2 diabetes: a therapy concept for the future?
- 9 November 2023
- Published by Springer Nature in Die Diabetologie
- Vol. 20 (1) , 147-148
Once-weekly basal ultralong-acting insulin administration in type 2 diabetes: a therapy concept for the future?
- Open Access
- 23 October 2023
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 21 (1) , 1-7
Circulating acyl-CoA-binding protein/diazepam-binding inhibitor in gestational diabetes mellitus
Background: Acyl-CoA-binding protein (ACBP)/diazepam-binding inhibitor has recently been characterized as an endocrine factor affecting energy balance and lipid metabolism. However, regulation of ACBP in women with gestational diabetes mellitus (GDM) during pregnancy, as well as postpartum, has not been investigated, so far. Methods: ACBP was quantified in 74 women with GDM and 74 healthy, gestational age-matched, pregnant controls using an enzyme-linked immunosorbent assay. Furthermore, ACBP was quantified post-partum in 82 women (i.e. 41 women with previous GDM vs. 41 previous control women). ACBP was related to measures of obesity, hypertension, glucose and lipid metabolism, renal function, and inflammation during pregnancy and postpartum. Results: During pregnancy, median [interquartile range] ACBP levels were not significantly different in women with GDM (40.9 [40.0] µg/l) compared to healthy, pregnant controls (29.1 [32.3] µg/l) (p = 0.215). ACBP serum concentrations increased from 30.3 [40.5] µg/l during pregnancy to 59.7 [33.2] µg/l after pregnancy in the entire cohort (p < 0.001). This observed elevation was consistent across both subgroups of women, those with prior GDM and those without. Multivariate analysis revealed that homeostasis model assessment of beta cell function (HOMA2-B) and creatinine positively and independently correlated with serum ACBP after pregnancy, while multivariate analysis during pregnancy showed no significant correlations. Conclusions: Circulating ACBP is not a marker of GDM status, but ACBP is decreased during pregnancy, irrespective of GDM status. Furthermore, ACBP is related to beta cell function and renal markers in women after pregnancy.
- 23 October 2023
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 21 (1) , 1-7
Open AccessCirculating acyl-CoA-binding protein/diazepam-binding inhibitor in gestational diabetes mellitus
Background: Acyl-CoA-binding protein (ACBP)/diazepam-binding inhibitor has recently been characterized as an endocrine factor affecting energy balance and lipid metabolism. However, regulation of ACBP in women with gestational diabetes mellitus (GDM) during pregnancy, as well as postpartum, has not been investigated, so far. Methods: ACBP was quantified in 74 women with GDM and 74 healthy, gestational age-matched, pregnant controls using an enzyme-linked immunosorbent assay. Furthermore, ACBP was quantified post-partum in 82 women (i.e. 41 women with previous GDM vs. 41 previous control women). ACBP was related to measures of obesity, hypertension, glucose and lipid metabolism, renal function, and inflammation during pregnancy and postpartum. Results: During pregnancy, median [interquartile range] ACBP levels were not significantly different in women with GDM (40.9 [40.0] µg/l) compared to healthy, pregnant controls (29.1 [32.3] µg/l) (p = 0.215). ACBP serum concentrations increased from 30.3 [40.5] µg/l during pregnancy to 59.7 [33.2] µg/l after pregnancy in the entire cohort (p < 0.001). This observed elevation was consistent across both subgroups of women, those with prior GDM and those without. Multivariate analysis revealed that homeostasis model assessment of beta cell function (HOMA2-B) and creatinine positively and independently correlated with serum ACBP after pregnancy, while multivariate analysis during pregnancy showed no significant correlations. Conclusions: Circulating ACBP is not a marker of GDM status, but ACBP is decreased during pregnancy, irrespective of GDM status. Furthermore, ACBP is related to beta cell function and renal markers in women after pregnancy.
- Open Access
- 23 May 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1152444
Renal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor
Objective: Acyl-CoA-binding protein (ACBP)/diazepam-binding inhibitor has lately been described as an endocrine factor affecting food intake and lipid metabolism. ACBP is dysregulated in catabolic/malnutrition states like sepsis or systemic inflammation. However, regulation of ACBP has not been investigated in conditions with impaired kidney function, so far.Design/methods: Serum ACBP concentrations were investigated by enzyme-linked immunosorbent assay i) in a cohort of 60 individuals with kidney failure (KF) on chronic haemodialysis and compared to 60 individuals with a preserved kidney function; and ii) in a human model of acute kidney dysfunction (AKD). In addition, mACBP mRNA expression was assessed in two CKD mouse models and in two distinct groups of non-CKD mice. Further, mRNA expression of mACBP was measured in vitro in isolated, differentiated mouse adipocytes - brown and white - after exposure to the uremic agent indoxyl sulfate.Results: Median [interquartile range] serum ACBP was almost 20-fold increased in KF (514.0 [339.3] µg/l) compared to subjects without KF (26.1 [39.1] µg/l) (pmACBP mRNA expression in different tissues of CKD mice in vivo or in indoxyl sulfate-treated adipocytes in vitro.Conclusions: Circulating ACBP inversely associates with renal function, most likely through renal retention of the cytokine. Future studies need to investigate ACBP physiology in malnutrition-related disease states, such as CKD, and to adjust for markers of renal function.
- 23 May 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1152444
Open AccessRenal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor
Objective: Acyl-CoA-binding protein (ACBP)/diazepam-binding inhibitor has lately been described as an endocrine factor affecting food intake and lipid metabolism. ACBP is dysregulated in catabolic/malnutrition states like sepsis or systemic inflammation. However, regulation of ACBP has not been investigated in conditions with impaired kidney function, so far.Design/methods: Serum ACBP concentrations were investigated by enzyme-linked immunosorbent assay i) in a cohort of 60 individuals with kidney failure (KF) on chronic haemodialysis and compared to 60 individuals with a preserved kidney function; and ii) in a human model of acute kidney dysfunction (AKD). In addition, mACBP mRNA expression was assessed in two CKD mouse models and in two distinct groups of non-CKD mice. Further, mRNA expression of mACBP was measured in vitro in isolated, differentiated mouse adipocytes - brown and white - after exposure to the uremic agent indoxyl sulfate.Results: Median [interquartile range] serum ACBP was almost 20-fold increased in KF (514.0 [339.3] µg/l) compared to subjects without KF (26.1 [39.1] µg/l) (pmACBP mRNA expression in different tissues of CKD mice in vivo or in indoxyl sulfate-treated adipocytes in vitro.Conclusions: Circulating ACBP inversely associates with renal function, most likely through renal retention of the cytokine. Future studies need to investigate ACBP physiology in malnutrition-related disease states, such as CKD, and to adjust for markers of renal function.
- 23 January 2023
- Published by Springer Nature in Die Diabetologie
- Vol. 19 (2) , 1-3
Effekte von Tirzepatid im Vergleich zu Insulin Glargin auf die Nierenfunktion bei Typ-2-Diabetes
- 23 January 2023
- Published by Springer Nature in Die Diabetologie
- Vol. 19 (2) , 1-3
Effekte von Tirzepatid im Vergleich zu Insulin Glargin auf die Nierenfunktion bei Typ-2-Diabetes